Document Detail

Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.
MedLine Citation:
PMID:  23419113     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: WHO Treatment Guidelines recommend that artemisinin-based combination therapies (ACTs) are used to treat uncomplicated Plasmodium falciparum malaria. Artemether plus lumefantrine (AL) is currently approved in 86 countries, with 30 of the 47 sub-Saharan African countries using it as first-line therapy, and 8 as second-line therapy. The dispersible formulation of AL that facilitates administration to infants and children, being simpler for caregivers to prepare and administer than crushed tablets, and easier for sick children and infants to take is discussed.
AREAS COVERED: A descriptive summary of available literature from sub-Saharan Africa demonstrates consistently high efficacy and safety for over a decade, with the majority of reported 28-day PCR-corrected cure rates being above 95%.
EXPERT OPINION: AL is an important antimalarial that will play a major role as countries move towards the elimination of malaria. Further advances in best practice of ACT use will come through strategies to prolong the longevity of ACTs, improved access to ACTs, new data on the use of ACTs in pregnancy, asymptomatic patients and novel paediatric formulations.
Bernhards Ogutu
Related Documents :
2610223 - An analysis of the relationship between proximal and distal motor control.
18492513 - Neurodevelopmental follow-up of very preterm infants after proactive treatment at a ges...
8233993 - Spondylometaphyseal dysplasia (kozlowski type): case report.
Publication Detail:
Type:  Journal Article; Review     Date:  2013-02-18
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  14     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-13     Completed Date:  2013-08-23     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  643-54     Citation Subset:  IM    
Kenya Medical Research Institute, Centre for Clinical Research, Nairobi, Kenya.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Africa South of the Sahara
Antimalarials / adverse effects,  therapeutic use*
Artemisinins / adverse effects,  therapeutic use*
Drug Therapy, Combination
Ethanolamines / adverse effects,  therapeutic use*
Fluorenes / adverse effects,  therapeutic use*
Malaria, Falciparum / drug therapy*,  parasitology
Plasmodium falciparum / drug effects*
Practice Guidelines as Topic
Treatment Outcome
Reg. No./Substance:
0/Antimalarials; 0/Artemisinins; 0/Ethanolamines; 0/Fluorenes; C7D6T3H22J/artemether; F38R0JR742/lumefantrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fungal biotransformation of zinc silicate and sulfide mineral ores.
Next Document:  Dihydroquercetin (DHQ) induce HO-1 and NQO1 expression against oxidative stress through the Nrf2-dep...